The global diabetes market is experiencing a surge driven by the increasing prevalence of this chronic disease. At the forefront of this evolution are leading companies of GLP-1 receptor agonists, a class of drugs that https://tirzepatidepharma.com/index.php/product/nrt-active-antibacterial-quit-smoking-aid-nad/